Studied for
2 endpoints · 3 findings · 2 papers · 2 null
- Serum adiponectinno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- Total testosteronelowersEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
What the evidence says
How to read these marks3 findings · 2 endpoints · 2 papers · 2 null · by evidence strength
What moved
1 finding
Decreases total testosterone
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“In females with PCOS, atorvastatin lowered the total testosterone, FAI, androstenedione, and DHEAS.”
Quoted verbatim from Effect of atorvastatin on testosterone levels.. - Study
- meta-analysis
- Population
- Females with polycystic ovary syndrome in four randomised trials (mean age 32 years), atorvastatin daily for at least three weeks versus placebo or no treatment
Effect of atorvastatin on testosterone levels.2021PMID:33482034Permalink
What did not
2 findings
No detected effect on serum adiponectin
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Meta-analysis with a random-effect model showed that atorvastatin did not significantly affect circulating adiponectin as compared with controls (WMD = − 0.27 μg/mL, 95% CI: − 0.89 to 0.35 μg/mL, p = 0.39; Fig. 2a).”
Quoted verbatim from Effect of atorvastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 to 80 mg/day, 4 to 30 weeks
- Population
- Patients with various conditions (hyperlipidaemia, type 2 diabetes, hypertension, coronary artery disease, rheumatoid arthritis) in ten randomised trials, 14 datasets, oral atorvastatin versus placebo or blank control
Effect -0.27 mean difference, 95% CI -0.89 to 0.35
Effect of atorvastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.2019PMID:31870381Permalink
No detected effect on total testosterone
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“We found no significant difference between atorvastatin and placebo on the levels of total testosterone in males.”
Quoted verbatim from Effect of atorvastatin on testosterone levels.. - Study
- meta-analysis
- Population
- Males in two randomised trials (normal lipid profile or mild dyslipidaemia; mean age 68 years), atorvastatin daily for at least three weeks versus placebo or no treatment
Effect of atorvastatin on testosterone levels.2021PMID:33482034Permalink
Papers screened
1,447 papers
- Compound
- atorvastatin
- Screened
- 1,447
- Admitted
- 3
- Discarded
- 94
- Not read
- 1,350
- Showing
- 200 of 1,447
Produced a finding3 papers
- PMID:318703812026-10-05
- PMID:334820342026-10-05
- PMID:341288632026-10-05
Discarded: no extractable result44 papers
- PMID:26554793claims extracted but refused by the deterministic validators2026-10-05
- PMID:28658127no claim extracted — narrated_not_pooled2026-10-05
- PMID:29535505claims extracted but refused by the deterministic validators2026-10-05
- PMID:38165842claims extracted but the two passes did not agree2026-10-05
- NCT00166036declared_contrast×2 — no posted analysis compares a atorvastatin arm with a placebo/no-intervention arm and carries a p-value (Atorvastatin 10 mg=unmatched, Pravastatin 80 mg=unmatched)2026-10-03
- NCT00289900declared_contrast×25 — no posted analysis compares a atorvastatin arm with a placebo/no-intervention arm and carries a p-value (MK-0524B 2g/20 mg=EXPERIMENTAL, MK-0524B 2g/40mg=EXPERIMENTAL, Atorvastatin 10 mg=ACTIVE_COMPARATOR+subject, Atorvastatin 20 mg=ACTIVE_COMPARATOR+subject, Atorvastatin 40 mg=ACTIVE_COMPARATOR+sub2026-10-03
- NCT00296400declared_contrast×72 — no posted analysis compares a atorvastatin arm with a placebo/no-intervention arm and carries a p-value (Rosuvastatin 10 mg=unmatched, Rosuvastatin 40 mg=unmatched, Atorvastatin 80 mg=unmatched)2026-10-03
- NCT00300469declared_contrast×8 — no posted analysis compares a atorvastatin arm with a placebo/no-intervention arm and carries a p-value (ABT-335 + 20 mg Atorvastatin=unmatched, ABT-335 + 40 mg Atorvastatin=unmatched, ABT-335=unmatched, 20 mg Atorvastatin=unmatched, 40 mg Atorvastatin=unmatched, 80 mg Atorvastatin=unmatched)2026-10-03
- NCT00319449declared_contrast×3 — no posted analysis compares a atorvastatin arm with a placebo/no-intervention arm and carries a p-value (Ezetimibe 10 mg=EXPERIMENTAL+subject, Placebo 10 mg=PLACEBO_COMPARATOR+subject)2026-10-03
- NCT00344370declared_contrast×2 — no posted analysis compares a atorvastatin arm with a placebo/no-intervention arm and carries a p-value (Pitavastatin 4 mg=unmatched, Atorvastatin 40 mg=unmatched)2026-10-03
- NCT00395486declared_contrast×12 — no posted analysis compares a atorvastatin arm with a placebo/no-intervention arm and carries a p-value (Rosuvastatin=EXPERIMENTAL, Atorvastatin=ACTIVE_COMPARATOR+subject)2026-10-03
- NCT00412841declared_contrast×4 — no posted analysis compares a atorvastatin arm with a placebo/no-intervention arm and carries a p-value (Atorvastatin=EXPERIMENTAL+subject, Placebo=PLACEBO_COMPARATOR)2026-10-03
and 32 more.
Discarded: the wrong intervention24 papers
- PMID:30448890no claim extracted — combination_exposure2026-10-05
- NCT00127218intervention×1 — no declared intervention names atorvastatin2026-10-03
- NCT00442897intervention×1 — no declared intervention names atorvastatin2026-10-03
- NCT00530946intervention×1 — no declared intervention names atorvastatin2026-10-03
- NCT00559962intervention×1 — no declared intervention names atorvastatin2026-10-03
- NCT00652327intervention×1 — no declared intervention names atorvastatin2026-10-03
- NCT00850460intervention×1 — no declared intervention names atorvastatin2026-10-03
- NCT00862251intervention×1 — no declared intervention names atorvastatin2026-10-03
- NCT01047501intervention×1 — no declared intervention names atorvastatin2026-10-03
- NCT01218204intervention×1 — no declared intervention names atorvastatin2026-10-03
- NCT01341730intervention×1 — no declared intervention names atorvastatin2026-10-03
- NCT01342211intervention×1 — no declared intervention names atorvastatin2026-10-03
and 12 more.
Discarded: another reason, stated per paper19 papers
- PMID:35178452no claim extracted — cause not determined2026-10-05
- NCT00185731design×1 — allocation NA -- not randomised2026-10-03
- NCT00540293design×1 — allocation NON_RANDOMIZED -- not randomised2026-10-03
- NCT00576576design×1 — allocation NA -- not randomised2026-10-03
- NCT00728910design×1 — allocation NON_RANDOMIZED -- not randomised2026-10-03
- NCT00739999design×1 — allocation NA -- not randomised2026-10-03
- NCT00770679design×1 — allocation NA -- not randomised2026-10-03
- NCT01107743design×1 — studyType OBSERVATIONAL -- only INTERVENTIONAL is extracted2026-10-03
- NCT01163851design×1 — allocation NA -- not randomised2026-10-03
- NCT01304641design×1 — studyType OBSERVATIONAL -- only INTERVENTIONAL is extracted2026-10-03
- NCT01527045design×1 — allocation NA -- not randomised2026-10-03
- NCT01795937design×1 — allocation NON_RANDOMIZED -- not randomised2026-10-03
and 7 more.
Discarded: no comparator6 papers
- PMID:30326894no claim extracted — comparator_not_absence2026-10-05
- PMID:30580373no claim extracted — comparator_not_absence2026-10-05
- PMID:31354240no claim extracted — comparator_not_absence2026-10-05
- NCT00703261declared_contrast×1, arm_count×1 — 1 arm(s) -- nothing to compare against2026-10-03
- PMID:35606846no claim extracted — comparator_not_absence2026-09-29
- PMID:42723012no claim extracted — comparator_not_absence2026-09-29
Discarded: an endpoint this vocabulary does not hold1 paper
- PMID:35104501claims extracted but the object named resolved to no node — recorded in candidate_nodes (ADR-0070)2026-09-29
Not read yet1,350 papers
- PMID:180709402026-10-05
- PMID:211304542026-10-04
- PMID:237041712026-10-04
- PMID:227057302026-10-03
- PMID:211930432026-10-03
- PMID:215361322026-10-03
- PMID:217674402026-10-03
- PMID:220045092026-10-03
- PMID:187964502026-10-03
- PMID:215709622026-10-01
- PMID:186767732026-09-29
- PMID:172448772026-09-29
and 1,338 more.
Measured, not recorded
- Compound
- atorvastatin
- Endpoints measured
- 270 endpoints
- Recorded as a finding
- No
Show what was measured
carotid intima-media thickness change
decreases
Adjuvant treatment with atorvastatin was associated with a significant reduction in CIMT (WMD = −0.17, 95% CI: −0.22 to−0.12)
PMID:26554793 · one of two readings recorded this
carotid intima-media thickness change
decreases
High-dose atorvastatin treatment was associated with a significant decrease in CIMT (WMD = −0.17, 95% CI: −0.32 to −0.02)
PMID:26554793 · one of two readings recorded this
carotid intima-media thickness change
decreases
reduced WMD of CIMT to −0.21 mm (95% CI: −0.22 to −0.12) among patients complicated with carotid atherosclerosis, −0.18 mm (95% CI: −0.23 to −0.14) among patients complicated with dyslipidemia, and −0.15 mm (95% CI: −0.22 to −0.08) among type 2 diabetic patients
PMID:26554793 · one of two readings recorded this
carotid intima-media thickness change
decreases
reduced WMD of CIMT to −0.21 mm (95% CI: −0.22 to −0.12) among patients complicated with carotid atherosclerosis, −0.18 mm (95% CI: −0.23 to −0.14) among patients complicated with dyslipidemia, and −0.15 mm (95% CI: −0.22 to −0.08) among type 2 diabetic patients
PMID:26554793 · one of two readings recorded this
carotid intima-media thickness change
decreases
reduced WMD of CIMT to −0.21 mm (95% CI: −0.22 to −0.12) among patients complicated with carotid atherosclerosis, −0.18 mm (95% CI: −0.23 to −0.14) among patients complicated with dyslipidemia, and −0.15 mm (95% CI: −0.22 to −0.08) among type 2 diabetic patients
PMID:26554793 · one of two readings recorded this
carotid intima-media thickness, high-dose versus low-dose atorvastatin, 4 trials
decreases, WMD -0.17; 95% CI -0.32 to -0.02
Not recorded as a finding: Dose-versus-dose comparison; both arms receive atorvastatin, so comparator is not absence of the compound
High-dose atorvastatin treatment was associated with a significant decrease in CIMT (WMD = −0.17, 95% CI: −0.32 to −0.02).
PMID:26554793 · one of two readings recorded this
fasting plasma glucose change
no effect
There were no significant differences in the changes of FPG, PPG, and HA1c between the 2 groups
PMID:26554793 · one of two readings recorded this
fasting plasma glucose, postprandial glucose and HbA1c, atorvastatin versus control
no effect
Not recorded as a finding: the only sentence is agentless ('between the 2 groups') and gives no estimate
There were no significant differences in the changes of FPG, PPG, and HA1c between the 2 groups.
PMID:26554793 · one of two readings recorded this
glycosylated hemoglobin change
no effect
There were no significant differences in the changes of FPG, PPG, and HA1c between the 2 groups
PMID:26554793 · one of two readings recorded this
HDL-C change
increases
increase in HDL-C (WMD = 0.10 mmol/L, 95% CI: 0.00 to 0.20)
PMID:26554793 · one of two readings recorded this
high-dose versus low-dose atorvastatin on CIMT, 4 trials
decreases, WMD -0.17, 95% CI -0.32 to -0.02
Not recorded as a finding: dose-versus-dose comparator, both arms exposed
High-dose atorvastatin treatment was associated with a significant decrease in CIMT (WMD = −0.17, 95% CI: −0.32 to −0.02).
PMID:26554793 · one of two readings recorded this
LDL change
decreases
LDL (WMD = −0.64 mmol/L, 95% CI: −1.16 to −0.12)
PMID:26554793 · one of two readings recorded this
postprandial plasma glucose change
no effect
There were no significant differences in the changes of FPG, PPG, and HA1c between the 2 groups
PMID:26554793 · one of two readings recorded this
serum hs-CRP change
decreases
adjuvant treatment with atorvastatin was associated with a significant decrease in hs-CRP (SMD −3.26 mg/L, 95% CI: −4.78 to −1.74) in a random effects model
PMID:26554793 · one of two readings recorded this
serum hs-CRP, pooled SMD, 5 trials
decreases, SMD -3.26 mg/L; 95% CI -4.78 to -1.74
Not recorded as a finding: Paragraph describes high-dose versus low-dose arms (236 vs 230) while the sentence says atorvastatin versus control, so the comparator is internally inconsistent; the unit (mg/L) on an SMD is also inconsistent
As shown in Figure 5, adjuvant treatment with atorvastatin was associated with a significant decrease in hs-CRP (SMD −3.26 mg/L, 95% CI: −4.78 to −1.74) in a random effects model.
PMID:26554793 · one of two readings recorded this
serum hs-CRP, pooled SMD in 5 trials
decreases, SMD -3.26 mg/L, 95% CI -4.78 to -1.74
Not recorded as a finding: the paper's text describes these 5 trials as high-dose versus low-dose while its figure legend says atorvastatin versus control, so the comparator is unclear
As shown in Figure 5, adjuvant treatment with atorvastatin was associated with a significant decrease in hs-CRP (SMD −3.26 mg/L, 95% CI: −4.78 to −1.74) in a random effects model.
PMID:26554793 · one of two readings recorded this
total cholesterol change
decreases
TC (WMD = −1.19 mmol/L, 5% CI −1.79 to −0.60)
PMID:26554793 · one of two readings recorded this
total cholesterol, triglycerides, LDL and HDL-C change, pooled WMD, atorvastatin add-on versus control
TC WMD -1.19 mmol/L; LDL WMD -0.64 mmol/L; HDL-C WMD 0.10 mmol/L (95% CI 0.00 to 0.20)
Not recorded as a finding: The sentence says 'significant increase' in TC, TG and LDL while the estimates are negative or inconsistent in sign, and HDL-C interval touches zero (0.00 to 0.20); direction words contradict the estimates
Overall, adjuvant treatment with atorvastatin was associated with a significant increase in TC (WMD = −1.19 mmol/L, 5% CI −1.79 to −0.60), TG (WMD = 0.53 mmol/L, 95% CI: −0.95 to −0.12), and LDL (WMD = −0.64 mmol/L, 95% CI: −1.16 to −0.12) and increase in HDL-C (WMD = 0.10 mmol/L, 95% CI: 0.00 to 0.20).
PMID:26554793 · one of two readings recorded this
triglyceride change
decreases
TG (WMD = 0.53 mmol/L, 95% CI: −0.95 to −0.12)
PMID:26554793 · one of two readings recorded this
burr-hole drainage
decreases
The odds ratio (OR) of burr-hole drainage was 0.143 (95% confidence interval [CI]: 0.021–0.958) with atorvastatin intervention
PMID:28658127 · one of two readings recorded this
hematoma improvement rate at third month
no effect, p = 0.0977
the improvement rate of hematoma at third months after atorvastatin administration was 75% for the atorvastatin group versus 42% for the control group; however, the result did not have any statistically significant difference (P =.0977)
PMID:28658127 · one of two readings recorded this
hematoma recurrence
decreases, n = 102
1 study with 102 patients described that atorvastatin used as an adjunct to surgery could significantly decrease the risks of recurrence or prolong the time-to-recurrence hematoma
PMID:28658127 · one of two readings recorded this
hematoma volume
decreases, n = 22
hematoma volume reduced from 48.70 ± 20.38 to 16.64 ± 14.28 mL with a sample size of 22 within the first month of atorvastatin treatment
PMID:28658127 · one of two readings recorded this
hematoma volume
decreases, n = 7
the volume of hematoma was reduced from 20.83 ± 4.49 to 11.40 ± 4.46 mL with a sample size of 7 within the first month of oral administration of atorvastatin, 20 mg daily
PMID:28658127 · one of two readings recorded this
patients undergoing surgery due to deterioration
They reported that 1 patient was underwent surgery due to deteriorating condition with an increasing volume of hematoma
PMID:28658127 · one of two readings recorded this
patients with improved symptoms and no recurrence
22 patients experienced improved symptoms and did not have recurrence during the follow-up period after atorvastatin intervention
PMID:28658127 · one of two readings recorded this
postoperative improvement rate
increases
The postoperative improvement rate was 97.4% (38/39) in atorvastatin group versus 80.9% (51/63) in control group
PMID:28658127 · one of two readings recorded this
risk of deterioration requiring surgery
decreases
the risk of deterioration requiring surgery was 16.7% in atorvastatin group versus 58.3% in control group
PMID:28658127 · one of two readings recorded this
risk of uncured CSDH with antiplatelet or anticoagulant history
no effect
the history of antiplatelet or anticoagulant did not increase the risk of uncured CSDH, and the OR was 0.329 (95% CI = 0.040–2.696)
PMID:28658127 · one of two readings recorded this
contrast-induced acute kidney injury prevalence, all nine RCTs pooled, atorvastatin versus pooled control
decreases, OR 0.46; 95% CI 0.27-0.79, p = 0.004
Not recorded as a finding: Control group pools placebo and low-dose statin arms (Methods), so the comparator is not absence of the compound; the placebo-only high-dose stratum was recorded instead
Pooling the data from all nine RCTs showed that atorvastatin could reduce the risk of CIAKI (OR 0.46; 95% CI 0.27–0.79; p=0.004) compared with the control group.
PMID:29535505 · one of two readings recorded this
contrast-induced acute kidney injury prevalence
decreases, p = 0.004
Pooling the data from all nine RCTs showed that atorvastatin could reduce the risk of CIAKI (OR 0.46; 95% CI 0.27–0.79; p=0.004) compared with the control group
PMID:29535505 · one of two readings recorded this
contrast-induced acute kidney injury prevalence
decreases, p = 0.04
High-dose atorvastatin reduced the risk of CIAKI (OR 0.45; 95% CI 0.21–0.95; p=0.04) when compared with the placebo group
PMID:29535505 · one of two readings recorded this
contrast-induced AKI, all nine trials pooled, atorvastatin versus control (placebo or low-dose statin)
decreases, OR 0.46, 95% CI 0.27-0.79, p = 0.004
Not recorded as a finding: comparator pools placebo with low-dose statin, so it is not a contrast against absence of the compound
Pooling the data from all nine RCTs showed that atorvastatin could reduce the risk of CIAKI (OR 0.46; 95% CI 0.27–0.79; p=0.004) compared with the control group.
PMID:29535505 · one of two readings recorded this
HDL-C change from baseline
increases, p = 0.002
The results showed that the overall efficacy was significant difference between combination and monotherapy (MD = 0.95, 95% CI: 0.34 to 1.57, P = 0.002)
PMID:30326894 · one of two readings recorded this
HDL-C change from baseline
no effect, p = 0.909
E10+A10/A20, P = 0.001; E10+A10/A10, P = 0.909; E10+A20/A40, P = 0.178; E10+A40/A80, P = 0.522
PMID:30326894 · one of two readings recorded this
HDL-C change from baseline
increases, p = 0.0003
the E10 + A10 vs. A20 group was the most obvious (MD = 1.58, 95% CI: 0.72 to 2.44, P = 0.0003), by subgroup
PMID:30326894 · one of two readings recorded this
HDL-C change from baseline
no effect, p = 0.178
E10+A10/A20, P = 0.001; E10+A10/A10, P = 0.909; E10+A20/A40, P = 0.178; E10+A40/A80, P = 0.522
PMID:30326894 · one of two readings recorded this
HDL-C change from baseline
no effect, p = 0.522
E10+A10/A20, P = 0.001; E10+A10/A10, P = 0.909; E10+A20/A40, P = 0.178; E10+A40/A80, P = 0.522
PMID:30326894 · one of two readings recorded this
HDL-C treatment difference
no effect
Blagden,M.D., 2007,UK,25 | randomised, double-blind, parallel-group, placebocontrolled | E10 + A10/A10 | 72 | 76 | −14.1 | (− 17.9,-10.2) | −0.3 | (−4.3,3.6) | −9.2 | (− 12.4,-6) | −8.3 | NR
PMID:30326894 · one of two readings recorded this
HDL-C treatment difference
no effect
Conard,S.E., 2008,USA,27 | multicenter, randomized, double-blind, parallel-group | E10 + A20/A40 | 92 | 92 | −20 | (−25,-15) | 2 | (−2,7) | −12 | (− 16,− 9) | -9 | (− 18,0)
PMID:30326894 · one of two readings recorded this
HDL-C treatment difference
no effect
Leiter,L.A., 2008,Canada,29 | multicenter, randomized, double-blind, parallel-group | E10 + A40/A80 | 277 | 279 | −16 | (−19,-13) | 0 | (−1,2) | −10 | (− 12,-8) | − 7 | (− 11,-3)
PMID:30326894 · one of two readings recorded this
HDL-C treatment difference
no effect
Matsue,Y., 2013,Japan,19 | randomized, open-labeled, parallel-group | E10 + A10/A20 | 115 | 128 | −16.7 | (−18.34,-15.06) | 0.47 | (−2.05,2.99) | −9.6 | (−11.07,-8.13) | −5.3 | (− 9.59,-1.01)
PMID:30326894 · one of two readings recorded this
HDL-C treatment difference
no effect
Padhy,B.M., 2013,India,24 | randomised, double-blind, parallel-group, comparator-controlled | E10 + A10/A10 | 15 | 15 | −19.9 | (−32.4,-7.4) | 6.3 | (−7.2,19.8) | −14.4 | (−27.7,-1) | −33 | (−54.1,-11.9)
PMID:30326894 · one of two readings recorded this
HDL-C treatment difference
no effect
Stein,E., 2004,Spain,23 | multicenter, randomized, double-blind, active-controlled | E10 + A10/A20 | 293 | 303 | −14.8 | (− 16.74,-12.86) | 0.8 | (− 0.86,2.46) | − 11.2 | (− 12.86,-9.54) | −5.4 | (− 10.11,-0.69)
PMID:30326894 · one of two readings recorded this
HDL-C treatment difference
no effect
Teramoto,T., 2012,Japan,20 | multicenter, randomized, open-label, parallel-group | E10 + A10/A20 | 47 | 46 | −10.6 | (−15.4,-5.8) | 4 | (−0.3,8.3) | − 7.6 | (− 11.4,− 3.8) | -3 | (−18.8,12.7)
PMID:30326894 · one of two readings recorded this
HDL-C treatment difference
increases
Zieve,F., 2010,Russia,22 | multicenter, randomized, doubleblind, parallel-arm | E10 + A10/A20 | 515 | 515 | − 14 | (− 16,-12) | 2 | (0.3,4) | −8 | (− 9,-7) | −6 | (− 9,-3)
PMID:30326894 · one of two readings recorded this
LDL-C change from baseline
decreases, p = 0.0001
Pooled data using a fixed-effects model displayed that combination therapy led to a significant reduction in LDL-C (MD = − 15.38, 95% CI: -16.17 to − 14.60, P < 0.0001)
PMID:30326894 · one of two readings recorded this
LDL-C change from baseline
decreases, p = 0.0001
E10+A10/A20, P < 0.0001; E10+A10/A10, P < 0.0001; E10+A20/A40, P < 0.0001; E10+A40/A80, P < 0.0001
PMID:30326894 · one of two readings recorded this
LDL-C change from baseline
decreases, p = 0.0001
E10+A10/A20, P < 0.0001; E10+A10/A10, P < 0.0001; E10+A20/A40, P < 0.0001; E10+A40/A80, P < 0.0001
PMID:30326894 · one of two readings recorded this
LDL-C change from baseline
decreases, p = 0.0001
the E10 + A20 vs. A40 group was the most obvious (MD = − 19.94, 95% CI: -23.61 to − 16.27, P < 0.0001), by subgroup
PMID:30326894 · one of two readings recorded this
LDL-C change from baseline
decreases, p = 0.0001
E10+A10/A20, P < 0.0001; E10+A10/A10, P < 0.0001; E10+A20/A40, P < 0.0001; E10+A40/A80, P < 0.0001
PMID:30326894 · one of two readings recorded this
LDL-C treatment difference
decreases
Blagden,M.D., 2007,UK,25 | randomised, double-blind, parallel-group, placebocontrolled | E10 + A10/A10 | 72 | 76 | −14.1 | (− 17.9,-10.2) | −0.3 | (−4.3,3.6) | −9.2 | (− 12.4,-6) | −8.3 | NR
PMID:30326894 · one of two readings recorded this
LDL-C treatment difference
decreases
Conard,S.E., 2008,USA,27 | multicenter, randomized, double-blind, parallel-group | E10 + A20/A40 | 92 | 92 | −20 | (−25,-15) | 2 | (−2,7) | −12 | (− 16,− 9) | -9 | (− 18,0)
PMID:30326894 · one of two readings recorded this
LDL-C treatment difference
decreases
Leiter,L.A., 2008,Canada,29 | multicenter, randomized, double-blind, parallel-group | E10 + A40/A80 | 277 | 279 | −16 | (−19,-13) | 0 | (−1,2) | −10 | (− 12,-8) | − 7 | (− 11,-3)
PMID:30326894 · one of two readings recorded this
LDL-C treatment difference
decreases
Matsue,Y., 2013,Japan,19 | randomized, open-labeled, parallel-group | E10 + A10/A20 | 115 | 128 | −16.7 | (−18.34,-15.06) | 0.47 | (−2.05,2.99) | −9.6 | (−11.07,-8.13) | −5.3 | (− 9.59,-1.01)
PMID:30326894 · one of two readings recorded this
LDL-C treatment difference
decreases
Padhy,B.M., 2013,India,24 | randomised, double-blind, parallel-group, comparator-controlled | E10 + A10/A10 | 15 | 15 | −19.9 | (−32.4,-7.4) | 6.3 | (−7.2,19.8) | −14.4 | (−27.7,-1) | −33 | (−54.1,-11.9)
PMID:30326894 · one of two readings recorded this
LDL-C treatment difference
decreases
Stein,E., 2004,Spain,23 | multicenter, randomized, double-blind, active-controlled | E10 + A10/A20 | 293 | 303 | −14.8 | (− 16.74,-12.86) | 0.8 | (− 0.86,2.46) | − 11.2 | (− 12.86,-9.54) | −5.4 | (− 10.11,-0.69)
PMID:30326894 · one of two readings recorded this
LDL-C treatment difference
decreases
Teramoto,T., 2012,Japan,20 | multicenter, randomized, open-label, parallel-group | E10 + A10/A20 | 47 | 46 | −10.6 | (−15.4,-5.8) | 4 | (−0.3,8.3) | − 7.6 | (− 11.4,− 3.8) | -3 | (−18.8,12.7)
PMID:30326894 · one of two readings recorded this
LDL-C treatment difference
decreases
Zieve,F., 2010,Russia,22 | multicenter, randomized, doubleblind, parallel-arm | E10 + A10/A20 | 515 | 515 | − 14 | (− 16,-12) | 2 | (0.3,4) | −8 | (− 9,-7) | −6 | (− 9,-3)
PMID:30326894 · one of two readings recorded this
total cholesterol change from baseline
decreases, p = 0.0001
There was significant difference between combination and monotherapy (MD = − 9.51, 95% CI: -10.28 to − 8.74, P < 0.0001)
PMID:30326894 · one of two readings recorded this
total cholesterol change from baseline
decreases, p = 0.0001
E10+A10/A20, P < 0.0001; E10+A10/A10, P < 0.0001; E10+A20/A40, P < 0.0001; E10+A40/A80, P < 0.0001
PMID:30326894 · one of two readings recorded this
total cholesterol change from baseline
decreases, p = 0.0001
E10+A10/A20, P < 0.0001; E10+A10/A10, P < 0.0001; E10+A20/A40, P < 0.0001; E10+A40/A80, P < 0.0001
PMID:30326894 · one of two readings recorded this
total cholesterol change from baseline
decreases, p = 0.0001
the E10 + A20 vs. A40 group was the most obvious (MD = − 12.11, 95% CI: -14.65 to − 9.58, P < 0.0001), by subgroup
PMID:30326894 · one of two readings recorded this
total cholesterol change from baseline
decreases, p = 0.0001
E10+A10/A20, P < 0.0001; E10+A10/A10, P < 0.0001; E10+A20/A40, P < 0.0001; E10+A40/A80, P < 0.0001
PMID:30326894 · one of two readings recorded this
total cholesterol treatment difference
decreases
Blagden,M.D., 2007,UK,25 | randomised, double-blind, parallel-group, placebocontrolled | E10 + A10/A10 | 72 | 76 | −14.1 | (− 17.9,-10.2) | −0.3 | (−4.3,3.6) | −9.2 | (− 12.4,-6) | −8.3 | NR
PMID:30326894 · one of two readings recorded this
total cholesterol treatment difference
decreases
Conard,S.E., 2008,USA,27 | multicenter, randomized, double-blind, parallel-group | E10 + A20/A40 | 92 | 92 | −20 | (−25,-15) | 2 | (−2,7) | −12 | (− 16,− 9) | -9 | (− 18,0)
PMID:30326894 · one of two readings recorded this
total cholesterol treatment difference
decreases
Leiter,L.A., 2008,Canada,29 | multicenter, randomized, double-blind, parallel-group | E10 + A40/A80 | 277 | 279 | −16 | (−19,-13) | 0 | (−1,2) | −10 | (− 12,-8) | − 7 | (− 11,-3)
PMID:30326894 · one of two readings recorded this
total cholesterol treatment difference
decreases
Matsue,Y., 2013,Japan,19 | randomized, open-labeled, parallel-group | E10 + A10/A20 | 115 | 128 | −16.7 | (−18.34,-15.06) | 0.47 | (−2.05,2.99) | −9.6 | (−11.07,-8.13) | −5.3 | (− 9.59,-1.01)
PMID:30326894 · one of two readings recorded this
total cholesterol treatment difference
decreases
Padhy,B.M., 2013,India,24 | randomised, double-blind, parallel-group, comparator-controlled | E10 + A10/A10 | 15 | 15 | −19.9 | (−32.4,-7.4) | 6.3 | (−7.2,19.8) | −14.4 | (−27.7,-1) | −33 | (−54.1,-11.9)
PMID:30326894 · one of two readings recorded this
total cholesterol treatment difference
decreases
Stein,E., 2004,Spain,23 | multicenter, randomized, double-blind, active-controlled | E10 + A10/A20 | 293 | 303 | −14.8 | (− 16.74,-12.86) | 0.8 | (− 0.86,2.46) | − 11.2 | (− 12.86,-9.54) | −5.4 | (− 10.11,-0.69)
PMID:30326894 · one of two readings recorded this
total cholesterol treatment difference
decreases
Teramoto,T., 2012,Japan,20 | multicenter, randomized, open-label, parallel-group | E10 + A10/A20 | 47 | 46 | −10.6 | (−15.4,-5.8) | 4 | (−0.3,8.3) | − 7.6 | (− 11.4,− 3.8) | -3 | (−18.8,12.7)
PMID:30326894 · one of two readings recorded this
total cholesterol treatment difference
decreases
Zieve,F., 2010,Russia,22 | multicenter, randomized, doubleblind, parallel-arm | E10 + A10/A20 | 515 | 515 | − 14 | (− 16,-12) | 2 | (0.3,4) | −8 | (− 9,-7) | −6 | (− 9,-3)
PMID:30326894 · one of two readings recorded this
triglyceride change from baseline
decreases, p = 0.0001
combination therapy led to a significant reduction in TG (MD = − 6.42, 95% CI: -7.78 to − 5.06, P < 0.0001)
PMID:30326894 · one of two readings recorded this
triglyceride change from baseline
decreases, p = 0.0001
E10+A10/A20, P < 0.0001; E10+A20/A40, P = 0.004; E10+A40/A80, P < 0.0001
PMID:30326894 · one of two readings recorded this
triglyceride change from baseline
decreases, p = 0.002
the E10 + A20 vs. A40 group was the most obvious (MD = − 9.16, 95% CI: -15.33 to − 2.98, P = 0.002), by subgroup
PMID:30326894 · one of two readings recorded this
triglyceride change from baseline
decreases, p = 0.0001
E10+A10/A20, P < 0.0001; E10+A20/A40, P = 0.004; E10+A40/A80, P < 0.0001
PMID:30326894 · one of two readings recorded this
triglyceride treatment difference
decreases
Blagden,M.D., 2007,UK,25 | randomised, double-blind, parallel-group, placebocontrolled | E10 + A10/A10 | 72 | 76 | −14.1 | (− 17.9,-10.2) | −0.3 | (−4.3,3.6) | −9.2 | (− 12.4,-6) | −8.3 | NR
PMID:30326894 · one of two readings recorded this
triglyceride treatment difference
no effect
Conard,S.E., 2008,USA,27 | multicenter, randomized, double-blind, parallel-group | E10 + A20/A40 | 92 | 92 | −20 | (−25,-15) | 2 | (−2,7) | −12 | (− 16,− 9) | -9 | (− 18,0)
PMID:30326894 · one of two readings recorded this
triglyceride treatment difference
decreases
Leiter,L.A., 2008,Canada,29 | multicenter, randomized, double-blind, parallel-group | E10 + A40/A80 | 277 | 279 | −16 | (−19,-13) | 0 | (−1,2) | −10 | (− 12,-8) | − 7 | (− 11,-3)
PMID:30326894 · one of two readings recorded this
triglyceride treatment difference
decreases
Matsue,Y., 2013,Japan,19 | randomized, open-labeled, parallel-group | E10 + A10/A20 | 115 | 128 | −16.7 | (−18.34,-15.06) | 0.47 | (−2.05,2.99) | −9.6 | (−11.07,-8.13) | −5.3 | (− 9.59,-1.01)
PMID:30326894 · one of two readings recorded this
triglyceride treatment difference
decreases
Padhy,B.M., 2013,India,24 | randomised, double-blind, parallel-group, comparator-controlled | E10 + A10/A10 | 15 | 15 | −19.9 | (−32.4,-7.4) | 6.3 | (−7.2,19.8) | −14.4 | (−27.7,-1) | −33 | (−54.1,-11.9)
PMID:30326894 · one of two readings recorded this
triglyceride treatment difference
decreases
Stein,E., 2004,Spain,23 | multicenter, randomized, double-blind, active-controlled | E10 + A10/A20 | 293 | 303 | −14.8 | (− 16.74,-12.86) | 0.8 | (− 0.86,2.46) | − 11.2 | (− 12.86,-9.54) | −5.4 | (− 10.11,-0.69)
PMID:30326894 · one of two readings recorded this
triglyceride treatment difference
no effect
Teramoto,T., 2012,Japan,20 | multicenter, randomized, open-label, parallel-group | E10 + A10/A20 | 47 | 46 | −10.6 | (−15.4,-5.8) | 4 | (−0.3,8.3) | − 7.6 | (− 11.4,− 3.8) | -3 | (−18.8,12.7)
PMID:30326894 · one of two readings recorded this
triglyceride treatment difference
decreases
Zieve,F., 2010,Russia,22 | multicenter, randomized, doubleblind, parallel-arm | E10 + A10/A20 | 515 | 515 | − 14 | (− 16,-12) | 2 | (0.3,4) | −8 | (− 9,-7) | −6 | (− 9,-3)
PMID:30326894 · one of two readings recorded this
completed study (n)
Completed, n (%) | 1097 (87.5) | 899 (91.0) | 474 (85.9) | 312 (82.3) | 2782 (87.7)
PMID:30448890 · one of two readings recorded this
DBP change from baseline (LOCF)
decreases
The mean (SD) change in DBP for LOCF was − 8.8 (9.8) mmHg in CONFIDENCE II, − 8.5 (8.6) mmHg in PROTECT I, − 10.1 (9.0) mmHg in STH I, − 8.5 (9.6) mmHg in STH II
PMID:30448890 · one of two readings recorded this
DBP change from baseline (LOCF)
decreases
and − 8.9 (9.3) mmHg in the merged FAS
PMID:30448890 · one of two readings recorded this
DBP change from baseline (LOCF)
decreases
The mean (SD) change in DBP for LOCF was − 8.8 (9.8) mmHg in CONFIDENCE II, − 8.5 (8.6) mmHg in PROTECT I, − 10.1 (9.0) mmHg in STH I, − 8.5 (9.6) mmHg in STH II
PMID:30448890 · one of two readings recorded this
DBP change from baseline (LOCF)
decreases
The mean (SD) change in DBP for LOCF was − 8.8 (9.8) mmHg in CONFIDENCE II, − 8.5 (8.6) mmHg in PROTECT I, − 10.1 (9.0) mmHg in STH I, − 8.5 (9.6) mmHg in STH II
PMID:30448890 · one of two readings recorded this
DBP change from baseline (LOCF)
decreases
The mean (SD) change in DBP for LOCF was − 8.8 (9.8) mmHg in CONFIDENCE II, − 8.5 (8.6) mmHg in PROTECT I, − 10.1 (9.0) mmHg in STH I, − 8.5 (9.6) mmHg in STH II
PMID:30448890 · one of two readings recorded this
DBP change from baseline (Visit 2)
decreases
Corresponding mean (SD) decreases in DBP observed at Visit 2 ranged from a minimum of − 6.4 (9.2) mmHg (STH II) to a maximum − 8.6 (8.5) mmHg (STH I)
PMID:30448890 · one of two readings recorded this
DBP change from baseline (Visit 2)
decreases
Corresponding mean (SD) decreases in DBP observed at Visit 2 ranged from a minimum of − 6.4 (9.2) mmHg (STH II) to a maximum − 8.6 (8.5) mmHg (STH I)
PMID:30448890 · one of two readings recorded this
DBP change from baseline (Visit 3)
decreases
At Visit 3, mean (SD) changes in DBP from baseline were − 9.2 (9.8) mmHg (CONFIDENCE II), − 8.7 (8.3) mmHg (PROTECT I), − 10.3 (8.9) mmHg (STH I), and − 8.7 (9.8) mmHg (STH II)
PMID:30448890 · one of two readings recorded this
DBP change from baseline (Visit 3)
decreases
At Visit 3, mean (SD) changes in DBP from baseline were − 9.2 (9.8) mmHg (CONFIDENCE II), − 8.7 (8.3) mmHg (PROTECT I), − 10.3 (8.9) mmHg (STH I), and − 8.7 (9.8) mmHg (STH II)
PMID:30448890 · one of two readings recorded this
DBP change from baseline (Visit 3)
decreases
At Visit 3, mean (SD) changes in DBP from baseline were − 9.2 (9.8) mmHg (CONFIDENCE II), − 8.7 (8.3) mmHg (PROTECT I), − 10.3 (8.9) mmHg (STH I), and − 8.7 (9.8) mmHg (STH II)
PMID:30448890 · one of two readings recorded this
DBP change from baseline (Visit 3)
decreases
At Visit 3, mean (SD) changes in DBP from baseline were − 9.2 (9.8) mmHg (CONFIDENCE II), − 8.7 (8.3) mmHg (PROTECT I), − 10.3 (8.9) mmHg (STH I), and − 8.7 (9.8) mmHg (STH II)
PMID:30448890 · one of two readings recorded this
lost to follow up (n)
Lost to follow up, n (%) | 121 (9.7) | 65 (6.6) | 78 (14.1) | 45 (11.8) | 309 (9.7)
PMID:30448890 · one of two readings recorded this
SBP change from baseline (LOCF)
decreases
mean (SD) change from baseline in SBP was − 17.4 (14.6), − 17.6 (12.6), − 20.1 (13.2) and − 18.5 (13.9) mmHg in the CONFIDENCE II, PROTECT I, STH I, and STH II studies, respectively
PMID:30448890 · one of two readings recorded this
SBP change from baseline (LOCF)
decreases
with a resultant change in the merged FAS of − 18.0 (13.7) mmHg
PMID:30448890 · one of two readings recorded this
SBP change from baseline (LOCF)
decreases
mean (SD) change from baseline in SBP was − 17.4 (14.6), − 17.6 (12.6), − 20.1 (13.2) and − 18.5 (13.9) mmHg in the CONFIDENCE II, PROTECT I, STH I, and STH II studies, respectively
PMID:30448890 · one of two readings recorded this
SBP change from baseline (LOCF)
decreases
mean (SD) change from baseline in SBP was − 17.4 (14.6), − 17.6 (12.6), − 20.1 (13.2) and − 18.5 (13.9) mmHg in the CONFIDENCE II, PROTECT I, STH I, and STH II studies, respectively
PMID:30448890 · one of two readings recorded this
SBP change from baseline (LOCF)
decreases
mean (SD) change from baseline in SBP was − 17.4 (14.6), − 17.6 (12.6), − 20.1 (13.2) and − 18.5 (13.9) mmHg in the CONFIDENCE II, PROTECT I, STH I, and STH II studies, respectively
PMID:30448890 · one of two readings recorded this
SBP change from baseline (Visit 2)
decreases
followed by comparable decreases in CONFIDENCE II, PROTECT I, and STH II at both Visit 2 (− 13.9 [13.9]; − 13.1 [12.7]; − 13.7 [13.5] mmHg, respectively)
PMID:30448890 · one of two readings recorded this
SBP change from baseline (Visit 2)
decreases
followed by comparable decreases in CONFIDENCE II, PROTECT I, and STH II at both Visit 2 (− 13.9 [13.9]; − 13.1 [12.7]; − 13.7 [13.5] mmHg, respectively)
PMID:30448890 · one of two readings recorded this
SBP change from baseline (Visit 2)
decreases
highest in STH I (Visit 2: − 17.0 [12.5] mmHg; Visit 3: − 20.2 [13.1] mmHg)
PMID:30448890 · one of two readings recorded this
SBP change from baseline (Visit 2)
decreases
followed by comparable decreases in CONFIDENCE II, PROTECT I, and STH II at both Visit 2 (− 13.9 [13.9]; − 13.1 [12.7]; − 13.7 [13.5] mmHg, respectively)
PMID:30448890 · one of two readings recorded this
SBP change from baseline (Visit 3)
decreases
and Visit 3 (− 18.0 [14.6]; − 17.4 [12.1]; − 18.5 [14.0] mmHg, respectively)
PMID:30448890 · one of two readings recorded this
SBP change from baseline (Visit 3)
decreases
and Visit 3 (− 18.0 [14.6]; − 17.4 [12.1]; − 18.5 [14.0] mmHg, respectively)
PMID:30448890 · one of two readings recorded this
SBP change from baseline (Visit 3)
decreases
highest in STH I (Visit 2: − 17.0 [12.5] mmHg; Visit 3: − 20.2 [13.1] mmHg)
PMID:30448890 · one of two readings recorded this
SBP change from baseline (Visit 3)
decreases
and Visit 3 (− 18.0 [14.6]; − 17.4 [12.1]; − 18.5 [14.0] mmHg, respectively)
PMID:30448890 · one of two readings recorded this
target BP achieved (LOCF)
LOCF | N = 1177 802 (68.1) | N = 866 676 (78.1) | N = 527 408 (77.4) | N = 362 256 (70.7) | N = 2932 2142 (73.1)
PMID:30448890 · one of two readings recorded this
target BP achieved (LOCF)
LOCF | N = 1177 802 (68.1) | N = 866 676 (78.1) | N = 527 408 (77.4) | N = 362 256 (70.7) | N = 2932 2142 (73.1)
PMID:30448890 · one of two readings recorded this
target BP achieved (LOCF)
LOCF | N = 1177 802 (68.1) | N = 866 676 (78.1) | N = 527 408 (77.4) | N = 362 256 (70.7) | N = 2932 2142 (73.1)
PMID:30448890 · one of two readings recorded this
target BP achieved (LOCF)
LOCF | N = 1177 802 (68.1) | N = 866 676 (78.1) | N = 527 408 (77.4) | N = 362 256 (70.7) | N = 2932 2142 (73.1)
PMID:30448890 · one of two readings recorded this
target BP achieved (LOCF)
LOCF | N = 1177 802 (68.1) | N = 866 676 (78.1) | N = 527 408 (77.4) | N = 362 256 (70.7) | N = 2932 2142 (73.1)
PMID:30448890 · one of two readings recorded this
target BP achieved (Visit 2)
Visit 2 | N = 1171 635 (54.2) | N = 864 504 (58.3) | N = 500 328 (65.6) | N = 345 173 (50.1) | N = 2880 1640 (56.9)
PMID:30448890 · one of two readings recorded this
target BP achieved (Visit 2)
Visit 2 | N = 1171 635 (54.2) | N = 864 504 (58.3) | N = 500 328 (65.6) | N = 345 173 (50.1) | N = 2880 1640 (56.9)
PMID:30448890 · one of two readings recorded this
target BP achieved (Visit 2)
Visit 2 | N = 1171 635 (54.2) | N = 864 504 (58.3) | N = 500 328 (65.6) | N = 345 173 (50.1) | N = 2880 1640 (56.9)
PMID:30448890 · one of two readings recorded this
target BP achieved (Visit 2)
Visit 2 | N = 1171 635 (54.2) | N = 864 504 (58.3) | N = 500 328 (65.6) | N = 345 173 (50.1) | N = 2880 1640 (56.9)
PMID:30448890 · one of two readings recorded this
target BP achieved (Visit 2)
Visit 2 | N = 1171 635 (54.2) | N = 864 504 (58.3) | N = 500 328 (65.6) | N = 345 173 (50.1) | N = 2880 1640 (56.9)
PMID:30448890 · one of two readings recorded this
target BP achieved (Visit 3)
Visit 3 | N = 982 702 (71.5) | N = 740 592 (80.0) | N = 433 347 (80.1) | N = 288 207 (71.9) | N = 2443 1848 (75.6)
PMID:30448890 · one of two readings recorded this
target BP achieved (Visit 3)
Visit 3 | N = 982 702 (71.5) | N = 740 592 (80.0) | N = 433 347 (80.1) | N = 288 207 (71.9) | N = 2443 1848 (75.6)
PMID:30448890 · one of two readings recorded this
target BP achieved (Visit 3)
Visit 3 | N = 982 702 (71.5) | N = 740 592 (80.0) | N = 433 347 (80.1) | N = 288 207 (71.9) | N = 2443 1848 (75.6)
PMID:30448890 · one of two readings recorded this
target BP achieved (Visit 3)
Visit 3 | N = 982 702 (71.5) | N = 740 592 (80.0) | N = 433 347 (80.1) | N = 288 207 (71.9) | N = 2443 1848 (75.6)
PMID:30448890 · one of two readings recorded this
target BP achieved (Visit 3)
Visit 3 | N = 982 702 (71.5) | N = 740 592 (80.0) | N = 433 347 (80.1) | N = 288 207 (71.9) | N = 2443 1848 (75.6)
PMID:30448890 · one of two readings recorded this
withdrawn due to adverse event (n)
Adverse event | 23 (1.8) | 17 (1.7) | 0 (0.0) | 17 (4.5) | 57 (1.8)
PMID:30448890 · one of two readings recorded this
elevated serum alanine aminotransferase
no effect, p = 0.07
No significant differences were observed in terms of elevated liver ALT between high-dose atorvastatin therapy and the control group (OR=1.95, 95% CI: 0.95 to 4.03, P=0.07; I2=48%, Phet=0.12; Figure 8)
PMID:30580373 · one of two readings recorded this
final TIMI flow grade 3 after PCI
no effect, p = 0.36
high-dose atorvastatin did not provide an additional benefit in post-procedural TIMI flow grade 3 (OR=1.31, 95% CI: 0.73 to 2.36, P=0.36; I2=0%, Phet=0.54; Figure 7)
PMID:30580373 · one of two readings recorded this
peak CK-MB level
no effect, p = 0.13
there were 6 studies used for the quantitative analysis of the level of peak CK-MB in ACS patients after PCI (SMD −0.34; 95% CI: −0.79 to 0.10, P=0.13; I2=84%, Phet<0.00001; Figure 6)
PMID:30580373 · one of two readings recorded this
serum high-sensitivity C-reactive protein change (SMD), short-term MACEs, peak CK-MB, final TIMI flow grade 3 and ALT elevation, high-dose atorvastatin preloading versus control (placebo or low-dose atorvastatin) in ACS patients undergoing PCI
decreases, SMD -1.59; 95% CI -2.38 to -0.80
Not recorded as a finding: the comparison was against another active treatment
Overall, high-dose atorvastatin reduced serum hs-CRP level in ACS patients after PCI (SMD −1.59; 95% CI: −2.38 to −0.80; P<0.0001), and statistical heterogeneity was evident among these studies (P<0.00001, I2=97%; Figure 5).
PMID:30580373 · one of two readings recorded this
serum hs-CRP level after PCI in acute coronary syndrome, pooled SMD of high-dose atorvastatin pretreatment; control was placebo or low-dose atorvastatin, pooled together (also MACE, peak CK-MB, TIMI flow grade 3, ALT elevation)
decreases, SMD -1.59, 95% CI -2.38 to -0.80
Not recorded as a finding: the comparison was against another active treatment
Overall, high-dose atorvastatin reduced serum hs-CRP level in ACS patients after PCI (SMD −1.59; 95% CI: −2.38 to −0.80; P<0.0001), and statistical heterogeneity was evident among these studies (P<0.00001, I2=97%; Figure 5).
PMID:30580373 · one of two readings recorded this
serum hs-CRP level
decreases, p = 0.0001
Overall, high-dose atorvastatin reduced serum hs-CRP level in ACS patients after PCI (SMD −1.59; 95% CI: −2.38 to −0.80; P<0.0001)
PMID:30580373 · one of two readings recorded this
short-term major adverse cardiac events
decreases, p = 0.01
high-dose atorvastatin therapy led to a 28% relative reduction in MACEs compared with the control medical therapy (OR=0.72, 95% CI: 0.56 to 0.94, P=0.01; I2=51%, Phet=0.04; Figure 4)
PMID:30580373 · one of two readings recorded this
30-day all-cause mortality, 30-day myocardial infarction and 30-day MACE, pooled risk ratio or odds ratio, 80 mg atorvastatin loading before PCI in acute coronary syndrome
decreases, p = 0.015
Not recorded as a finding: the comparison was against another active treatment
Compared with the control group, the high dose of atorvastatin group had significantly reduced incidence of MI (RR: 0.73, 95% CI, 0.56–0.94, P=0.015; Figure 2B) based on the fixed-effects model.
PMID:31354240 · one of two readings recorded this
30-day myocardial infarction incidence, pooled risk ratio of loading-dose (80 mg) atorvastatin before PCI in acute coronary syndrome; control was placebo, lower-dose atorvastatin (10 or 20 mg) or no atorvastatin, pooled together
decreases, RR 0.73, 95% CI 0.56-0.94, p = 0.015
Not recorded as a finding: the comparison was against another active treatment
Compared with the control group, the high dose of atorvastatin group had significantly reduced incidence of MI (RR: 0.73, 95% CI, 0.56–0.94, P=0.015; Figure 2B) based on the fixed-effects model.
PMID:31354240 · one of two readings recorded this
All-cause mortality at 30 days
no effect, p = 0.73
There was a nonsignificant trend toward all-cause mortality reduction in the loading dose of atorvastatin group (risk ratio [RR]: 0.94, 95% CI, 0.69–1.30, P=0.73; Figure 2A)
PMID:31354240 · one of two readings recorded this
All-cause mortality incidence at 30 days
no effect
with an overall incidence of 3.0% (70 of 2,356) in the loading dose of atorvastatin group and 3.1% (75 of 2,383) in the control group
PMID:31354240 · one of two readings recorded this
MACE at 30 days
decreases, p = 0.026
a significantly lower MACE rate with a combined OR of 0.80 (95% CI: 0.66–0.97, P=0.026)
PMID:31354240 · one of two readings recorded this
MACE at 30 days
no effect, p = 0.179
for patients with NSTE-ACS, there was no significant difference in MACE between the high-dose atorvastatin group and the control group (OR: 0.65, 95% CI, 0.35–1.22, P=0.179
PMID:31354240 · one of two readings recorded this
MACE at 30 days
decreases, p = 0.022
the incidence of MACE was significantly lower in the high-dose atorvastatin group than in the control group (OR: 0.67, 95% CI, 0.48–0.94, P=0.022
PMID:31354240 · one of two readings recorded this
MACE incidence at 30 days
decreases
The overall incidence of MACE in the high dose of atorvastatin group was 6.7% (166 of 2,483), whereas in the control group, it was of 8.4% (210 of 2,508)
PMID:31354240 · one of two readings recorded this
Myocardial infarction at 30 days
decreases, p = 0.015
the high dose of atorvastatin group had significantly reduced incidence of MI (RR: 0.73, 95% CI, 0.56–0.94, P=0.015
PMID:31354240 · one of two readings recorded this
Circulating adiponectin, meta-regression on BMI
no effect, p = 0.69
BMI (kg/m2) | −0.056 | − 0.358 to 0.246 | 0.69
PMID:31870381 · one of two readings recorded this
Circulating adiponectin, meta-regression on dose
no effect, p = 0.75
Dose (mg/d) | 0.0038 | −0.0218 to 0.0294 | 0.75
PMID:31870381 · one of two readings recorded this
Circulating adiponectin, meta-regression on duration
no effect, p = 0.95
Duration (weeks) | −0.0023 | −0.0734 to 0.0688 | 0.95
PMID:31870381 · one of two readings recorded this
Circulating adiponectin, meta-regression on male proportion
no effect, p = 0.11
Male (%) | −0.056 | − 0.122 to 0.010 | 0.11
PMID:31870381 · one of two readings recorded this
Circulating adiponectin, meta-regression on mean age
no effect, p = 0.35
Mean age (years) | −0.17 | −0.44 to 0.10 | 0.35
PMID:31870381 · one of two readings recorded this
Circulating adiponectin, meta-regression on number of subjects
no effect, p = 0.1
Number of subjects | − 0.019 | −0.043 to 0.005 | 0.10
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.39
WMD = − 0.27 μg/mL, 95% CI: − 0.89 to 0.35 μg/mL, p = 0.39
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.11
WMD = − 1.02 μg/mL, 95% CI: − 2.27 to 0.22 μg/mL, p = 0.11
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.29
10 mg | 6 (407) | 12% | −0.32 [− 0.92, 0.28] | 0.29
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.25
20 mg | 3 (206) | 84% | −1.15 [−3.11, 0.81] | 0.25
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.84
40 mg | 3 (159) | 75% | 0.67 [−1.18, 2.51] | 0.84
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.52
80 mg | 2 (159) | 0% | −0.35 [−1.42, 0.71] | 0.52 | 0.62
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.96
ELISA | 11 (720) | 38% | −0.01 [− 0.57, 0.54] | 0.96
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.2
RIA | 3 (211) | 85% | −1.48 [−3.74, 0.79] | 0.20 | 0.22
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.94
≤ 26 kg/m2 | 9 (535) | 57% | 0.03 [−0.65, 0.71] | 0.94
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.42
No | 12 (735) | 65% | −0.33 [−1.13, 0.47] | 0.42 | 0.70
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.66
Yes | 2 (196) | 0% | −0.13 [− 0.72, 0.46] | 0.66
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.4
≤ 8 weeks | 8 (520) | 0% | −0.19 [− 0.62, 0.24] | 0.40
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.81
≤ 52% | 8 (499) | 56% | 0.09 [−0.63, 0.81] | 0.81
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.97
≤ 56 years | 7 (419) | 80% | 0.02 [−1.13, 1.18] | 0.97
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.96
No | 9 (535) | 57% | 0.03 [−0.65, 0.71] | 0.96 | 0.18
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.13
Yes | 5 (396) | 59% | −0.95 [−2.18, 0.29] | 0.13
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.52
No | 7 (533) | 79% | −0.42 [−1.71, 0.87] | 0.52 | 0.84
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.24
Yes | 7 (398) | 0% | −0.28 [−0.75, 0.19] | 0.24
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.86
No | 10 (535) | 50% | 0.06 [−0.64, 0.77] | 0.86 | 0.14
PMID:31870381 · one of two readings recorded this
Circulating adiponectin
no effect, p = 0.11
Yes | 4 (396) | 73% | − 1.02 [−2.27, 0.22] | 0.11
PMID:31870381 · one of two readings recorded this
Total testosterone
decreases
atorvastatin may reduce total testosterone by -0.27 nmol/L (95% CI -0.50 to -0.04)
PMID:33482034 · one of two readings recorded this
Total testosterone
no effect
We found no significant difference in testosterone levels in males between atorvastatin and placebo, MD -0.20 nmol/L (95% CI -0.77 to 0.37)
PMID:33482034 · one of two readings recorded this
Androstenedione
decreases
androstenedione by -1.37 nmol/L (95% CI -2.26 to -0.49)
PMID:33482034 · one of two readings recorded this
SHBG
increases
atorvastatin increased SHBG concentrations in females by 3.11 nmol/L (95% CI 0.23 to 5.99)
PMID:33482034 · one of two readings recorded this
DHEAS
decreases
DHEAS by -0.63 μmol/l (95% CI -1.12 to -0.15)
PMID:33482034 · one of two readings recorded this
free androgen index, androstenedione and DHEAS in females with PCOS
decreases
Not recorded as a finding: no outcome node for free androgen index, androstenedione or DHEA sulphate
In females with PCOS, atorvastatin lowered the total testosterone, FAI, androstenedione, and DHEAS.
PMID:33482034 · both readings recorded this
Free androgen index (FAI)
decreases
FAI by -2.59 nmol/L (95% CI -3.62 to -1.57)
PMID:33482034 · one of two readings recorded this
sex hormone binding globulin in females, pooled MD
increases, MD 3.11 nmol/L, 95% CI 0.23 to 5.99
Not recorded as a finding: no SHBG outcome node in the list
Furthermore, compared to placebo, atorvastatin increased SHBG concentrations in females by 3.11 nmol/L (95% CI 0.23 to 5.99).
PMID:33482034 · one of two readings recorded this
sex hormone binding globulin (SHBG) concentration in females with PCOS
increases, 3.11 nmol/L (95% CI 0.23 to 5.99)
Not recorded as a finding: No outcome node for SHBG
Furthermore, compared to placebo, atorvastatin increased SHBG concentrations in females by 3.11 nmol/L (95% CI 0.23 to 5.99).
PMID:33482034 · one of two readings recorded this
HOMA-IR
decreases, p = 0.0001
PCOS patients in atorvastatin therapy group had lower HOMA-IR value than those in placebo group (SMD −4.12, 95% CI −6.00 to -2.23, P <.0001)
PMID:34128863 · one of two readings recorded this
BMI
no effect, p = 0.22
The BMI value showed insignificant decrease in the atorvastatin group compared to placebo group (SMD 0.12, 95% CI −0.07 to 0.31, P =.22)
PMID:34128863 · one of two readings recorded this
body mass index, pooled SMD, 7 trials
SMD 0.12, 95% CI -0.07 to 0.31, p = 0.22
Not recorded as a finding: Sentence calls the change an 'insignificant decrease' while the SMD is positive (0.12); direction word and signed estimate disagree and the result is not significant, so neither direction is recordable
The BMI value showed insignificant decrease in the atorvastatin group compared to placebo group (SMD 0.12, 95% CI −0.07 to 0.31, P =.22).
PMID:34128863 · one of two readings recorded this
body mass index, pooled SMD
SMD 0.12, 95% CI -0.07 to 0.31, p = 0.22
Not recorded as a finding: the sentence says 'insignificant decrease' beside a positive SMD of 0.12, so its direction word and its estimate disagree; neither no_effect nor a direction is safely anchorable
The BMI value showed insignificant decrease in the atorvastatin group compared to placebo group (SMD 0.12, 95% CI −0.07 to 0.31, P =.22).
PMID:34128863 · one of two readings recorded this
fasting glucose concentration, pooled SMD, 8 trials
no effect, SMD -0.06, 95% CI -0.31 to 0.20, p = 0.66
Not recorded as a finding: Sentence says atorvastatin 'did not reduce' fasting glucose, a one-sided negation that does not establish no_effect (rule 1a); no two-sided statement in the text
Compared with placebo, atorvastatin therapy did not reduce the fasting glucose concentration in PCOS patients dramatically (SMD -0.06, 95% CI -0.31 to 0.20, P =.66).
PMID:34128863 · one of two readings recorded this
Fasting glucose concentration
no effect, p = 0.66
Compared with placebo, atorvastatin therapy did not reduce the fasting glucose concentration in PCOS patients dramatically (SMD -0.06, 95% CI -0.31 to 0.20, P =.66)
PMID:34128863 · one of two readings recorded this
fasting insulin level, pooled SMD, 7 trials
decreases, SMD -1.84, 95% CI -3.06 to -0.62, p = 0.003
Not recorded as a finding: No outcome node for fasting insulin (only stimulated postprandial insulin exists)
Compared with placebo, atorvastatin therapy decreased fasting insulin level obviously (SMD -1.84, 95% CI -3.06 to -0.62, P =.003).
PMID:34128863 · one of two readings recorded this
fasting insulin level, pooled SMD
decreases, SMD -1.84, 95% CI -3.06 to -0.62, p = 0.003
Not recorded as a finding: no fasting-insulin outcome node in the list
Compared with placebo, atorvastatin therapy decreased fasting insulin level obviously (SMD -1.84, 95% CI -3.06 to -0.62, P =.003).
PMID:34128863 · one of two readings recorded this
Fasting insulin level
decreases, p = 0.003
Compared with placebo, atorvastatin therapy decreased fasting insulin level obviously (SMD -1.84, 95% CI -3.06 to -0.62, P =.003)
PMID:34128863 · one of two readings recorded this
Fasting insulin level
no effect, p = 0.09
Atorvastatin therapy decreased fasting insulin level significantly in 6 months subgroup (P =.03), but not in ≤3 months subgroup (P =.09)
PMID:34128863 · one of two readings recorded this
Fasting insulin level
decreases, p = 0.03
Atorvastatin therapy decreased fasting insulin level significantly in 6 months subgroup (P =.03), but not in ≤3 months subgroup (P =.09)
PMID:34128863 · one of two readings recorded this
Aβ42 aggregation (calcium-containing atorvastatin, Ator-Ca)
increases
As shown in Figure 1 A1, treatment with Ator-Ca accelerated the monomer consumption by shortening the initial stage without a significant effect on the middle stage.
PMID:35104501 · one of two readings recorded this
Aβ42 aggregation (monomer consumption, CD, ThT, TEM)
decreases
On the other hand, when calcium ions of Ator-Ca were scavenged, a concentration-dependent inhibitory effect of Ator on Aβ42 aggregation was observed.
PMID:35104501 · one of two readings recorded this
Aβ42 aggregation (NMR monomer consumption, CD spectroscopy, ThT fluorescence, TEM fibril count)
decreases, concentration-dependent inhibition; ThT intensity ~40% (125 μM) and ~20% (250 μM) of control at 10 h
At Ca-free Ator concentration of 125 μM (250 μM), a significant reduction in ThT intensity at 10 h was observed to about 40% (20%) of that of the control sample.
PMID:35104501 · one of two readings recorded this
Adverse events
decreases, p = 0.001
RR = 0.41, 95% CI: [0.3, 0.56], P < 0.001, I2 = 45.1%
PMID:35178452 · one of two readings recorded this
Blood calcium
no effect, p = 0.541
blood Ca-after treatment: SMD = 0.07, 95% CI: [-0.15, 0.29], P = 0.541, I2 = 0%
PMID:35178452 · one of two readings recorded this
Blood calcium
no effect, p = 0.854
blood Ca-before treatment: SMD = 0.02, 95% CI: [-0.2, 0.24], P = 0.854, I2 = 0%
PMID:35178452 · one of two readings recorded this
Blood phosphorus
no effect, p = 0.185
blood P-after treatment: SMD = 0.15, 95% CI: [-0.07, 0.38], P = 0.185, I2 = 0%
PMID:35178452 · one of two readings recorded this
Blood phosphorus
no effect, p = 0.953
blood P-before treatment: SMD = −0.01, 95% CI: [-0.23, 0.22], P = 0.953, I2 = 0%
PMID:35178452 · one of two readings recorded this
BMD femoral neck
increases, p = 0.001
12-month atorvastatin: SMD = 0.6, 95% CI: [0.34, 0.86], P < 0.001, I2 = 25.1%
PMID:35178452 · one of two readings recorded this
BMD femoral neck
no effect, p = 0.576
12-month atorvastatin: SMD = 0.07, 95% CI: [-0.18, 0.33], P = 0.576, I2 = 0%
PMID:35178452 · one of two readings recorded this
BMD femoral neck
increases, p = 0.001
6-month atorvastatin: SMD = 0.54, 95% CI: [0.39, 0.69], P < 0.001, I2 = 6.4%
PMID:35178452 · one of two readings recorded this
BMD femoral neck
no effect, p = 0.766
6-month atorvastatin: SMD = −0.02, 95% CI: [-0.17, 0.13], P = 0.766, I2 = 0%
PMID:35178452 · one of two readings recorded this
Sources cited
2 papers
- Subject
- atorvastatin
- Findings
- 3
- Papers
- 2